Promising results from 2 trials highlighting pomalidomide presented at ASH Celgene International Sarl (Nasdaq: CELG) today announced that its next IMiDs compound, pomalidomide, has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis. view more (2008-12-11)
